Patients With Urosepis and Received Ertapenem for Treatment
Conditions
Keywords
pharmacokinetic, pharmacodynamic, ertapenem, urosepsis
Brief summary
Ertapenem, a broad-spectrum carbapenem antibiotic, has shown promising in vitro activity agenst ESBL-producing Enterobacteriacae. This agent was licensed in United State of America and Europe for several clinical use in complicated intraabdominal infections, complicated skin and skin-structure infections, acute pelvic infections, complicated urinary tract infections and community-acquired pneumonia. In common with other beta-lactams, ertapenem exhibits primarily time-dependent activity, and the percentage of the exposure time during which the free drug concentration remain above the MIC (%T\>MIC) is the pharmacokinetic/pharmacodynamics (PK/PD) index that best correlates with efficacy. Pathophysiological changes in critically ill patients with severe infections resulting in altered PK patterns that may affect therapeutic plasma concentrations and achievement of PD have been found with several antimicrobial agents. The aim of the study was to determine the PK of ertapenem in patients with urosepsis.
Interventions
DRUGErtapenem Injection
1 g of ertapenem q24h, 30 min infusion
Sponsors
Prince of Songkla University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \>18 years of age * Diagnosis of urosepsis
Exclusion criteria
* They were pregnant * Circulatory shock (defined as a systolic blood pressure of \< 90 mmHg and pour tissue perfusion) * Documented hypersensitivity to carbapenems * Estimated creatinine clearance (CLcr) (determined by the Crockcroft-Goult method) of \< 30 mL/min
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Concentration of ertapenem in plasma | 48 hours after the ertapenem dose |
Countries
Thailand
Outcome results
None listed